In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

NeXagen acquires Vestar, two will merge to form NeXstar

Executive Summary

In a reverse merger of two biotech companies, NeXagen (drug discovery) will acquire Vestar (liposomal drug delivery) for about $96 million in stock. The two companies will merge to form NeXstar Pharmaceuticals Inc.
Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Liposomes
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Reverse Acquisition

Related Companies